Summary Ten human ovarian carcinoma cell lines have been studied as a potential in vitro screen for the development of novel anticancer platinum complexes. Lines have been established and developed both from solid and ascitic tumours, from pretreated and untreated patients, and are available at a range of in vitro passage numbers. The biological properties of the lines were consistent with them being human, epithelial and of ovarian carcinoma origin. Using a tritiated thymidine or leucine uptake method, and a 96 hour continuous drug exposure, the lines have been calibrated against four platinum-containing chemotherapeutic agents: cisplatin, iproplatin, carboplatin and tetraplatin. Striking differences in cytotoxicity were observed across the lines for each agent. Some lines were consistently resistant, others generally sensitive, whereas some showed clear evidence of differential sensitivity to a particular agent. Statistical analysis (Spearman rank correlation) involving the six possible pairings of drugs showed that cisplatin, iproplatin and carboplatin elicit a very similar pattern of response in these lines whereas tetraplatin elicits a completely different response pattern. Similar cytotoxicity values were obtained using a soft agar cloning assay. Results using a tetrazolium dye reduction assay, however, gave somewhat higher and more variable values, particularly with tetraplatin. The thymidine uptake assay will be adopted in further studies on a selected panel of six lines. This panel encompasses the spectra of sensitivities identified for each of the four agents against the original ten lines and may provide a useful screening facility for the development of novel platinum drugs, in that it detects both cell line-determined and structure-determined differences in cytotoxicity.
Traditionally, the development of new drugs for the treatment of malignant diseases has relied predominantly on transplantable murine tumour models, such as those used by the National Cancer Institute (NCI) (Frei, 1982; Venditti, 1983) . Such models include the P388 leukaemia, L1210 leukaemia, Lewis lung carcinoma, B16 melanoma, Colon 38 and CD8F1 mammary carcinoma. Our earlier work, which predicted the clinical antitumour activities of the platinum analogues JM8 (carboplatin) and JM9 (iproplatin), exploited predominantly the platinum-sensitive ADJ/PC6 murine plasmacytoma (Harrap et al., 1980; Harrap, 1985) . Other workers have generated cisplatin-resistant variants of the L1210 and P388 tumours in attempts to identify novel platinum drugs which might exhibit wider spectra of antitumour activities (Burchenal et al., 1979 (Burchenal et al., , 1980 . Tetraplatin exhibits no cross-resistance in such models and is currently under preclinical development at NCI (Anderson et al., 1986) . A recent reappraisal of screening models at the NCI has resulted in the replacement of the in vivo murine panel in favour of a range of in vitro human tumour cell lines representative of the major histological types (Boyd, 1986) .
Clinical trials using platinum-containing chemotherapeutic agents (mainly cisplatin and carboplatin) have thus far demonstrated good antitumour activity in testicular seminoma and teratoma (Wiltshaw & Carr, 1974; Peckham et al., 1985) , in ovarian carcinoma (with response rates typically around 50%) (Wiltshaw & Carr, 1974; Wiltshaw, 1985; Calvert et al., 1985) and lesser activity in other tumour types such as small cell lung cancer and carcinoma of the cervix. Future objectives in platinum drug development must embrace the discovery of agents which, in addition to possessing favourable normal cell toxicity profiles and similar antitumour activity to cisplatin, also show activity in disease currently resistant to cisplatin.
A panel of ovarian carcinoma cell lines representative of the spectrum of patient response to existing chemotherapy may be of relevance as an in vitro screen for new platinum-containing agents. There have been a number of recent reports describing the establishment of ovarian carcinoma cell lines (Woods et al., 1979; Simon et al., 1983; Van Haaften-Day et al., 1983; Buick et al., 1985; Wolf et al., 1987) . This study describes the development and biological properties of 10 human ovarian carcinoma cell lines. These have been obtained from both patient ascites and primary neoplasms, from patients having received chemotherapy before biopsy or no pretreatment. Six of the lines have also been established as xenograft lines in nude mice. .Their potential usefulness as a screen for the development of new platinum-containing chemotherapeutic agents has been assessed by calibrating the cell lines against four currently available agents: cisplatin, JM8 (carboplatin), JM9 (CHIP, iproplatin) and tetraplatin.
Materials and methods

Cell lines
Ten human ovarian carcinoma cell lines have been used in this study. (Fogh et al., 1977) , (Hamilton et al., 1983) and PAl (Zeuthen et al., 1980) were obtained from the American Type Culture Collection. OAW42 (Wilson, 1984) , OAW28, 41M and 59M were established by one the authors (A.P.W.). Details of these lines (OAW28, 41M and 59M) are in preparation for separate publication. PXN/94 and HX/62 were established from human ovarian xenograft lines grown in female nude (Nu/ Nu) mice in this department and CHI was established from an ascites sample within the department. Details of the tumour histology, source of biopsy and pre-and post-biopsy treatments are shown in Table I , which indicates that lines have been established from both solid and ascitic tumours, from xenograft lines, and from pretreated (chemotherapy and radiotherapy) or untreated patients.
All lines grew as monolayer cultures and, with the exception of 41M, were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (Imperial Laboratories, Salisbury, UK), 50 ig ml-1 gentamicin, 2.5 ig ml-1 amphotericin B, 2mM glutamine, plus Population doubling time Growth curves were constructed by seeding single cells at low density (1 x l0s per T25 flask). Cells in duplicate flasks were detached at 24-h intervals and counted using a Coulter counter.
Calibration of cell lines
Four platinum-containing agents were used: cisplatin (CDDP, neoplatin, cis-diamminedichloroplatinum (II)); iproplatin (JM9, CHIP, cis-dichloro-trans-dihydroxy-cis-bis (isopropylamine) platinum (IV)); carboplatin (JM8, CBDCA, paraplatin, cis-diammine-l ,1-cyclobutane dicarboxylatoplatinum (II)); and tetraplatin ((trans-d,l) 1,2-diaminocyclohexanetetrachloroplatinum (IV)) (Anderson et al., 1986 Drugs were dissolved at 1 mM in either 0.9% saline or water (for carboplatin) immediately before use. Assessment of cytotoxicity was then performed using a labelled thymidine or leucine uptake method as follows. Sub-confluent flasks of cells were disaggregated using 0.02% EDTA in 0.05% trypsin. Single cell suspensions were then produced by centrifugation (lOOg, 5min), resuspending in medium and gently passing through a 19-gauge needle. Viable cells were then counted using trypan blue dye exclusion and phase contrast microscopy, and seeded between 5 x 103 and 1 x 104 per well in 96-well plates (Nunc products) In addition to the labelled thymidine and leucine uptake assays, cytotoxicity was also assessed using a soft agar cell cloning assay (Salmon et al., 1978) involving exposure of cells to drug continuously for 14 days. Further, for means of comparison, cytotoxicity was determined using an assay based on the reduction of a soluble tetrazolium dye, XTT (sodium [(5-phenylaminocarbonyl) tetrazolium-2,3-diyl]-6-methoxy-4-nitrobenzene-3-sulphonate) (Scudiero et al., 1987) , kindly provided by Dr K. Paull (NCI). As with the thymidine and leucine assays drug exposure was for 96h.
Results
Biological properties All ten cell lines grew as attached monolayer cultures and possessed morphological features consistent with cells of epithelial origin. However, some differences in phase-contrast morphology were apparent. Some lines such as 41M, OAW28, PXN/94 and OVCAR-3 grew as small round cells within tightly adherent colonies, others such as SKOV-3 and HX/62 consisted of colonies containing much larger polygonal cells, CHI, OAW42, 59M and PA-1 were of intermediate morphology.
Characterisation of the lines with poly and monoclonal antibody markers is shown in Table II . In addition, the range in passage number used throughout this study for each line is shown. Table II shows that all lines were positive against the GCTM-1 antibody found to be specific for human cells. In addition, chromosome preparations for each of the 10 lines confirmed the presence of only human chromosomes. This reactivity is of particular relevance for those lines (PXN/94 and HX/62) which were established from xenograft lines. Intermediate filament analysis showed the lines to be positive (to varying degrees) for expression of low molecular weight acidic cytokeratins (found in cells of epithelial origin). In addition, with the exception of OAW28, lines showed positivity for vimentin expression.
The OC125 monoclonal antibody recognises the CA125 tumour marker which has been shown to be elevated in approximately 80% of non-mucinous epithelial ovarian carcinomas (Bast et al., 1981 (Bast et al., , 1983 Buamah et al., 1987) . Table  II shows that 9 of the 10 lines (OAW42 being the exception) possessed elevated levels of this marker. An additional marker that has been shown to possess some specificity toward ovarian carcinoma is the HMFG2 antigen with approximately 94% of epithelial ovarian carcinomas positive (Ward & Cruickshank, 1987; Ward et al., 1987) . Table II indicates that, as with CA125, 9 of the 10 lines express this antigen; for HMFG2 the CHI line is the exception.
Of the other marker antigens investigated, the oncofetal antigens AFP and CEA showed variable expression across the lines with approximately half positive for each antigen. Results with CEA are consistent with published studies which have shown elevated levels in 30-50% of epithelial ovarian tumours, particularly in poorly differentiated and advanced disease (Stall & Martin, 1981 In addition to the labelled uptake assays, cytotoxicity was determined for some of the lines using the XTT assay (a modification of the MTT assay) and by soft agar cell cloning. Results using these assays are shown in Table V , with the thymidine and leucine values also included for comparison. For the XTT assay, IC50 values were quite variable in comparison with the uptake assays. In general, values from the XTT assay were higher (up to 10-fold). In particular, determinations using tetraplatin were subject to the largest differences between the assays. However, for some lines and some agents (notably cisplatin) there was much closer agreement between the three assays.
A comparison of IC50 values obtained from the soft agar cloning assay and the uptake assays is shown in Table V Figure 3 . In this way, the higher the value the greater the sensitivity. Figure 3 (2.3-3.6) 10.3 (12-8.6) 6.3 (6.6-6.0) 3.9 (3.9-3.9) It is apparent that this panel of human ovarian tumour lines is capable of displaying both cell-determined and structure-determined differences in cytotoxicity to th-e four calibrating platinum species. As such it may provide a useful adjunct to other tumour models in the structure-activity ranking of potential new platinum-containing drugs. The mechanisms underlying the observed differences in cytotoxicity are unclear at present. Of the biological properties investigated (Table III) Slater, 1986; Nicolini, 1988) . The possible involvement of these factors remains to be determined.
Further to the uptake assays, cytotoxicity was compared using a modification of the MTT assay and by a soft agar clonogenic assay. The MTT assay has been proposed as a practicable alternative to the more conventional uptake or clonogenic assays for routine drug screening (Mossman, 1983; Ruben & Neubauer, 1987; Hill, 1987) . Indeed the NCI drug screening programme has recently adopted this assay (Alley et al., 1988) in preference to the more time consuming human tumour stem cell assay previously used (Salmon et al., 1978; Shoemaker et al., 1985) . In our hands the XTT assay produced IC50 values which were generally higher and more variable than the two uptake assays (Table V) . In particular, values involving tetraplatin were subject to the greatest variability. In contrast, data where the soft agar clonogenic assay of Salmon et al. (1978) was used (Table V) indicate a much closer agreement in IC50 value with the uptake assays. Notably, the high sensitivity of the PXN/94 line to tetraplatin is also apparent from the soft agar assay. In consideration of practicability, the variables inherent in the MTT assay as previously alluded to (Twentyman & Luscombe, 1987; Hill, 1987) have observed (particularly with tetraplatin) lead us to conclude that, for these lines, an assay endpoint involving thymidine uptake may be the most appropriate in a routine screening context. In conclusion, these cell lines may provide a useful component of a screening assay aimed at the discovery and development of novel platinum-containing chemotherapeutic agents. We propose to use the thymidine uptake assay and six lines for routine screening. The six lines chosen are SKOV-3 and HX/62, on the basis of their intrinsic resistance to the calibrating agents, 41M on the basis of sensitivity, PXN/94 and OVCAR-3 as they show evidence of differential sensitivity, and CH-1 as a representative of a number of lines of intermediate sensitivity. In addition, from Table I , it is apparent that these six lines are representative of tumours from both untreated and treated (chemotherapy and radiotherapy) patients, from solid xenograft tumours and ascites and (from Table II ) are usable at a range of in vitro passage number. In addition, five of these six lines (41M being the exception) have xenograft counterparts in the nude mouse, thus providing a directly comparable pharmacological model for the further assessment of interesting new agents.
